Quoin Pharmaceuticals
QNRX
2 hedge funds and large institutions have $106K invested in Quoin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
1,364% more capital invested
Capital invested by funds: $7.22K → $106K (+$98.4K)
2.06% more ownership
Funds ownership: 0.18% → 2.23% (+2.1%)
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$92.1K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$615 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.4K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$33 |
QNRX Hedge Fund Activity: Q4 2023 in Review
2 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q4 2023, worth a combined $106K — up 1,364% from $7.22K a quarter earlier.
Fund positioning in QNRX was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $92.1K. The largest seller was UBS Group, exiting entirely with an estimated $3.4K sold.
- 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $106K of Quoin Pharmaceuticals stock for Q4 2023, up 1,364% quarter-over-quarter.
- 1 fund opened new Quoin Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest Quoin Pharmaceuticals buyer in Q4 2023 was Susquehanna International Group, an estimated $92.1K added.
- The largest Quoin Pharmaceuticals seller in Q4 2023 was UBS Group, an estimated $3.4K sold.
Based on aggregated 13F filings for Q4 2023.